Effect of Butylphthalide on Serum MMP-9 IMA PPAR Gamma and Hemorrhagic Transformation in Patients with Acute Cerebral Infarction after Thrombolytic Therapy
Abstract：Objective: To investigate the effects of butylphthalide on serum matrix metalloproteinase-9 (MMP-9), ischemic modified albumin (IMA), peroxisome proliferator-activated receptor subtype-gamma (PPAR-gamma) and hemorrhagic transformation in patients with acute cerebral infarction after thrombolysis. Methods: 85 patients with acute cerebral infarction thrombolytic therapy in our hospital from June 2015 to June 2017 were selected as the study subjects. According to the random number table all the subjects were divided into observation group (n=45) and control group (n=40). The control group was treated with aitong thrombolytic therapy alone, and the observation group was treated with butylphthalide combined with aitong thrombolytic therapy. The clinical efficacy, serum mmp-9, IMA, PPAR renewal, haemorrhagic transformation, NIHSS score, modified Barthel index rating scale (MBI), neuron-specific enolase (NSE), S100B protein and glial fibrinolytic acid protein (GFAP) levels and complications of the two groups were compared. Results: After treatment, the total effective rate of the observation group was 93.33% higher than the control group's 75.00% (P<0.05). There was no significant difference in the levels of serum mp-9, IMA and PPAR prior to treatment between the two groups. After treatment, serum mmp-9 and IMA levels in both groups increased significantly, and serum PPAR tests in the observation group decreased significantly. Serum mp-9 and PPAR tests in the observation group were significantly lower than those in the control group, and IMA levels were significantly higher than those in the control group (P<0.05). The total incidence of hemorrhage transformation in the observation group was 8.89%, significantly lower than that in the control group (P<0.05). There was no significant difference in NIHSS and MBI scores between the two groups before treatment. After treatment, the NIHSS scores of the two groups decreased significantly, and the MBI scores increased significantly. Moreover, the NIHSS scores of the observation group were significantly lower than those of the control group, and the MBI scores were significantly higher than those of the control group (P<0.05). There was no significant difference in NSE, S100B and GFAP levels between the two groups before treatment. After treatment, the levels of NSE, S100B and GFAP in both groups decreased significantly, and the levels of NSE, S100B and GFAP in the observation group were significantly lower than those in the control group (P<0.05). The total complications in the observation group were 4.44%, significantly lower than the control group's 32.50% (P<0.05). Conclusion: The use of butylphthalide in patients with acute cerebral infarction with thrombolytic therapy has significant effects, and can improve the serum mmp-9, IMA, PPAR, and hemorrhagic transformation of patients. Therefore, it is worthy of clinical promotion.
孙战风, 袁鹰, 张金龙, 王丽, 唐超. 丁苯酞对急性脑梗死溶栓患者血清MMP-9 IMA PPARγ及出血性转化的影响[J]. 河北医学, 2019, 25(1): 37-41.
SUN Zhanfeng, YUAN Ying, ZHANG Jinlong, et al. Effect of Butylphthalide on Serum MMP-9 IMA PPAR Gamma and Hemorrhagic Transformation in Patients with Acute Cerebral Infarction after Thrombolytic Therapy. HeBei Med, 2019, 25(1): 37-41.
[1] 刘莉莉,徐蕾,王加梅.急性脑梗死患者丁苯酞静注治疗期间血浆NT-proBNP水平及NIHSS评分变化[J].山东医药,2015,55(47):46~48. [2] Naess H, Kurtz M, Thomassen L, et al. Serial NIHSS scores in patients with acute cerebral infarction[J]. Acta Neurologica Scandinavica, 2016, 133(6):415~420. [3] 陈庆友,张艳蕉,于熙莹.丁苯酞联合依达拉奉治疗急性脑梗死的临床研究[J].中国临床药理学杂志,2016,32(16):1453~1455. [4] 高长玉,吴成翰,赵建国,等.中国脑梗死中西医结合诊治指南(2017)[J].中国中西医结合杂志,2018,38(2):136~144. [5] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中国全科医学,2011,14(35):4013~4017. [6] Hori Y S, Kodera S, Sato Y, et al. Eosinopenia as a predictive factor of the short-term risk of mortality and infection after acute cerebral infarction[J]. Journal of Stroke & Cerebrovascular Diseases, 2016, 25(6):1307~1312. [7] 万长明.丁苯酞治疗急性脑梗死老年患者的疗效及对血清S100B、Hcy和ANG-1的影响[J].东南大学学报(医学版),2015,34(1):79~82. [8] Hori Y S, Kodera S, Sato Y, et al. Eosinopenia as a predictive factor of the short-term risk of mortality and infection after acute cerebral infarction[J]. Journal of Stroke & Cerebrovascular Diseases, 2016, 25(6):1307~1312. [9] 潘君枝,程超禅,陈瑞炳. 丁苯酞治疗对急性脑梗死患者血管内皮功能与血栓形成的影响[J]. 中国老年学杂志,2015,35(13):3580~3582. [10] Bong J B, Kang H G, Choo I S. Acute cerebral infarction after pyrethroid ingestion[J]. Geriatrics & Gerontology International, 2017, 17(3):510~511.
2019, Vol. 25 
冀公网安备13080202000677号